Acrivon Therapeutics Common Stock Statistics
Share Statistics
Acrivon Therapeutics Common Stock has 31.14M shares outstanding. The number of shares has increased by 40.32% in one year.
| Shares Outstanding | 31.14M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.31% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 21.96M |
| Failed to Deliver (FTD) Shares | 22 |
| FTD / Avg. Volume | 0.03% |
Short Selling Information
The latest short interest is 1.08M, so 3.48% of the outstanding shares have been sold short.
| Short Interest | 1.08M |
| Short % of Shares Out | 3.48% |
| Short % of Float | 4.97% |
| Short Ratio (days to cover) | 15.38 |
Valuation Ratios
The PE ratio is -1.8 and the forward PE ratio is -3.11.
| PE Ratio | -1.8 |
| Forward PE | -3.11 |
| PS Ratio | 0 |
| Forward PS | 272.4 |
| PB Ratio | 0.9 |
| P/FCF Ratio | -2.47 |
| PEG Ratio | n/a |
Enterprise Valuation
Acrivon Therapeutics Inc. Common Stock has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 9.75, with a Debt / Equity ratio of 0.01.
| Current Ratio | 9.75 |
| Quick Ratio | 9.75 |
| Debt / Equity | 0.01 |
| Total Debt / Capitalization | 0.72 |
| Cash Flow / Debt | -48.62 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.5% and return on capital (ROIC) is -53.43%.
| Return on Equity (ROE) | -0.5% |
| Return on Assets (ROA) | -0.44% |
| Return on Capital (ROIC) | -53.43% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.04M |
| Employee Count | 58 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 54.25% in the last 52 weeks. The beta is 1.7, so Acrivon Therapeutics Common Stock's price volatility has been higher than the market average.
| Beta | 1.7 |
| 52-Week Price Change | 54.25% |
| 50-Day Moving Average | 7.47 |
| 200-Day Moving Average | 7.6 |
| Relative Strength Index (RSI) | 47.99 |
| Average Volume (20 Days) | 83.02K |
Income Statement
In the last 12 months, Acrivon Therapeutics Common Stock had revenue of $0 and earned -$60.39M in profits. Earnings per share was $-2.74.
| Revenue | 0 |
| Gross Profit | -536.00K |
| Operating Income | -67.24M |
| Net Income | -60.39M |
| EBITDA | -59.85M |
| EBIT | - |
| Earnings Per Share (EPS) | -2.74 |
Balance Sheet
The company has $36.02M in cash and $4.64M in debt, giving a net cash position of $31.37M.
| Cash & Cash Equivalents | 36.02M |
| Total Debt | 4.64M |
| Net Cash | 31.37M |
| Retained Earnings | -116.42M |
| Total Assets | 214.68M |
| Working Capital | 174.16M |
Cash Flow
In the last 12 months, operating cash flow was -$42.64M and capital expenditures -$1.29M, giving a free cash flow of -$43.93M.
| Operating Cash Flow | -42.64M |
| Capital Expenditures | -1.29M |
| Free Cash Flow | -43.93M |
| FCF Per Share | -1.99 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
ACRV does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -38.7% |
| FCF Yield | -19.93% |
Analyst Forecast
The average price target for ACRV is $22, which is 210.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $22 |
| Price Target Difference | 210.7% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | 5.9 |
| Piotroski F-Score | 2 |